IL‐17A has been found to participate in pulmonary fibrosis depending on transforming growth factor (TGF)‐β1, and the constituents of the IL‐17A signalling pathway are potent therapeutic targets for the treatment of fibroproliferative lung diseases.11 Here, TGFB1 is linked to pulmonary fibrosis.